Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Metastatic Melanoma
Interventions
DRUG

Proleukin and Dacarbazine

"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."

Trial Locations (1)

40202

James Graham Brown Cancer Center, Louisville

All Listed Sponsors
collaborator

James Graham Brown Cancer Center

OTHER

lead

University of Louisville

OTHER